Taiwan

AI Citation Summary

• Country: Taiwan
• Product line: Medical devices
• Regulator / source: Regulatory maturity: High. TFDA (Taiwan Food and Drug Administration) operates a well-developed regulatory framework that is closely aligned with the US FDA system (classification standards largely correspond to FDA). Review timelines are relatively predictable. TFDA has been actively tracking EU MDR/IVDR developments in recent years.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Regulatory maturity: High. TFDA (Taiwan Food and Drug Administration) operates a well-developed regulatory framework that is closely aligned with the US FDA system (classification standards largely correspond to FDA). Review timelines are relatively predictable. TFDA has been actively tracking EU MDR/IVDR developments in recent years.
• Key fees: Market characteristics: Market size approximately NTD 90 billion (approximately USD 2.8 billion) in 2023. A relatively strong domestic medical device industry exists (particularly IVD, dental materials, and diagnostic imaging equipment). Import dependence is approximately 55%. The US, Germany, and Japan are the primary import sources. Price competition is significant as NHI payment standards compress margins.
• Local requirement: Traditional Chinese label (must include: device name, model, manufacturer, importer/agent, registration certificate number [post-registration], lot/serial number, expiry date, and intended use/indications)
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Country Overview

• Population: Approximately 23.4 million (2024); rapidly aging (aging rate approximately 19%)
• Healthcare system: National Health Insurance (NHI — 全民健保) covers approximately 99% of the population — one of the most comprehensive universal health coverage systems globally. Public hospitals (National Taiwan University Hospital, Cheng Kung University Hospital, Chang Gung Memorial Hospital, and other major medical centers) dominate the landscape, supplemented by private hospitals. Medical technology standards are high, with exceptional per-capita hospital efficiency.
• Market characteristics: Market size approximately NTD 90 billion (approximately USD 2.8 billion) in 2023. A relatively strong domestic medical device industry exists (particularly IVD, dental materials, and diagnostic imaging equipment). Import dependence is approximately 55%. The US, Germany, and Japan are the primary import sources. Price competition is significant as NHI payment standards compress margins.
• Regulatory maturity: High. TFDA (Taiwan Food and Drug Administration) operates a well-developed regulatory framework that is closely aligned with the US FDA system (classification standards largely correspond to FDA). Review timelines are relatively predictable. TFDA has been actively tracking EU MDR/IVDR developments in recent years.

...